NVCR: Regulatory Wins And Clinical Milestones Will Drive Oncology Expansion
NovoCure (NVCR) is seeing a modest upward revision in its analyst price target to $26.07, supported by improving procedure trends and anticipated growth in 2026, despite some analysts noting risks from sector rotation and policy changes. The company recently announced positive Phase 2 data for its Tumor Treating Fields therapy in pancreatic cancer, gained reimbursement approval in Japan for NSCLC, and received U.S. FDA approval for Optune Pax in pancreatic cancer, alongside issuing 2026 revenue guidance of $675-$705 million. These clinical and regulatory successes, coupled with expanding geographical reach and ongoing clinical development, are expected to drive long-term revenue stability and growth for NovoCure, though challenges like slow adoption and reimbursement uncertainty persist.
Japan approves a pancreatic cancer treatment from NovoCure (NVCR) after a trial showed longer survival.
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved NovoCure's Optune Pax for adults with unresectable locally advanced pancreatic cancer. This approval follows positive results from the Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in median overall survival for patients using Optune Pax alongside gemcitabine and nab-paclitaxel. The treatment, which uses Tumor Treating Fields, was well-tolerated with device-related skin adverse events being mostly mild to moderate.
A results call is set for 8 a.m. Oct. 29, when Novocure will discuss third-quarter results.
Novocure (Nasdaq: NVCR) is scheduled to release its third-quarter 2026 financial results on October 29, 2026, before U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure specializes in oncology, developing and commercializing Tumor Treating Fields therapy for aggressive cancers.
Japan approves a wearable device to use with chemo for advanced pancreatic cancer.
Novocure's Optune Pax, a wearable device delivering Tumor Treating Fields, has received approval in Japan for the treatment of unresectable locally advanced pancreatic cancer when used with gemcitabine and nab-paclitaxel. This approval follows positive results from the Phase 3 PANOVA-3 trial, which showed statistically significant improvement in overall survival for patients. The device is designed to disrupt cancer cell division without significantly affecting healthy cells, offering a new treatment option for this aggressive cancer.
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure's Optune Pax, a device that delivers Tumor Treating Fields (TTFields), has received approval in Japan for treating adult patients with unresectable locally advanced pancreatic cancer, in combination with gemcitabine and nab-paclitaxel. This approval follows positive results from the Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in overall survival and delayed pain progression for patients using Optune Pax. This marks a significant milestone, providing a new treatment option for a highly aggressive and often fatal cancer.
Tariff Cuts Put NovoCure Stock And Medical Exporters Back In Focus
Recent tariff cuts between the US and China are re-opening trade channels, specifically benefiting agricultural and medical exporters. This article highlights three US-listed stocks—SWS Hemodialysis Care (SHSE:688410), APT Medical (SHSE:688617), and NovoCure (NVCR)—that are poised to benefit from these policy changes. It encourages investors to examine these and other related companies to assess their altered risk and reward profiles.
ETFs Investing in NovoCure Ltd. Stocks
This article lists various ETFs that hold stocks of NovoCure Ltd., a medical specialties company. The table provides details such as market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return for each ETF. The information aims to help investors identify funds that offer diversified exposure to NovoCure Ltd. with potentially lower risk.
Discontinued operations of NovoCure Ltd. – HAN:038
This article states that NovoCure Ltd. (HAN:038) has discontinued its operations. It provides market data and other financial information related to the company on the Hannover Stock Exchange. The information is presented within the TradingView platform.
Price to earnings forward of NovoCure Ltd. – HAN:038
This article provides financial data for NovoCure Ltd. (stock symbol 038) listed on the Hannover Stock Exchange. It specifically highlights the company's price-to-earnings forward ratio. The content appears to be a financial data page from TradingView.
NovoCure stock reports 15.6 percent Q2 revenue growth
NovoCure reported a 15.6% increase in Q2 revenue to USD 183.58 million, surpassing consensus estimates. The company also announced a positive operating cash flow of USD 8.132 million, a significant improvement from the previous quarter, and outlined a plan to reach adjusted EBITDA break-even by year-end 2026. Despite remaining loss-making on a GAAP basis, the adjusted EPS beat expectations, and the positive cash flow indicates improving liquidity.
Is NovoCure (NVCR) Undervalued On TTFields Validation And Board Change?
NovoCure (NVCR) is back in focus following a board change and new validation for its TTFields therapy in various cancer indications. Despite a recent 23.86% year-to-date gain, the stock has seen an 86.01% decline over five years, raising questions about whether current gains are due to clinical validation or a market correction. The company is considered 38% undervalued by some, with a fair value of $26.07, banking on the wider adoption and reimbursement of its TTFields therapy.
NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall
NovoCure's stock has fallen 86% over the past five years, prompting questions about its current valuation relative to sales. Despite a P/S ratio similar to the Medical Equipment industry average, a tailored benchmark suggests NovoCure might be undervalued when considering its growth, margins, size, and risk. Investors are encouraged to consider these fundamentals and specific concerns raised by a broader review before making investment decisions.
NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change
NovoCure (NVCR) is considered 36% undervalued, trading at $16.67 against a fair value estimate of $26.07, despite a recent board change and some share price volatility. The company's future potential is linked to the validation of its TTFields therapy for new indications and projected market expansion. However, slower than hoped adoption and persistent losses pose risks to this valuation.
Growth Plan Might Change The Case For Investing In NovoCure Stock (NVCR)
NovoCure (NVCR) recently announced the retirement of director Timothy Scannell and revealed a refreshed operating roadmap focused on increasing glioblastoma device demand, expanding pancreatic and lung cancer launches, and achieving adjusted EBITDA break-even by year-end. The company's investment narrative now hinges on the broader adoption of its Tumor Treating Fields technology and its ability to manage costs to reach profitability. While analysts have varying revenue and earnings projections, the company's fair value suggests a potential 56% upside.
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
NovoCure outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference. The company aims for single-digit growth in its glioblastoma business, anticipates regulatory decisions for pancreatic cancer treatments in Japan, and is targeting at least adjusted EBITDA break-even by year-end. NovoCure's CEO Frank Leonard highlighted their Tumor Treating Fields technology and plans for international expansion and clinical trials, including combinations with KRAS inhibitors.
NovoCure (NASDAQ: NVCR) Announces Board Vacancy Following Timothy Scannell's Departure on September 2, 2026
NovoCure (NASDAQ: NVCR) has announced a board vacancy following the departure of Timothy Scannell, effective September 2, 2026. The company stated that Scannell's retirement was in accordance with the company's Articles of Association and was not due to any disagreements with management or the organization. Chief Financial Officer Christoph Brackmann authorized the report confirming the director seat was formally vacated.
NovoCure (NASDAQ: NVCR) director steps down with no dispute
NovoCure Ltd (NVCR) announced that director Timothy Scannell retired from its Board of Directors, effective September 2, 2026, after five years of service. The company explicitly stated that his retirement did not stem from any disagreement with NovoCure or its management. This information was disclosed in an 8-K filing.
Novocure Ltd Announces Retirement of Timothy Scannell from the Board, Effective September 2, 2026
Novocure Ltd. announced the retirement of Timothy Scannell from its Board of Directors, effective September 2, 2026. Mr. Scannell served for five years, and his departure was not due to any disagreements with the company or its management.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
Novocure Limited disclosed a cybersecurity incident in mid-August 2026, resulting in the exposure of internal patient IDs for over 1,400 U.S. patient records, additional identifying information for fewer than 50 other patients, and general contact information for healthcare providers and employees. The company stated that its medical treatment devices were not accessed and systems remained functional. This incident is part of a trend of cybersecurity breaches affecting the healthcare and medtech industries in 2026.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
Novocure Limited recently disclosed a cybersecurity incident in mid-August 2026, which exposed internal patient ID numbers for over 1,400 U.S. patient records, along with additional identifying information for fewer than 50 other patients. The breach also affected general contact information for healthcare providers and Novocure employees. Despite this, the company stated its medical treatment devices were not accessed, systems remained functional, and it does not anticipate a material financial impact, highlighting growing cybersecurity concerns in the healthcare industry.
News - Novocure discloses cyberattack exposing records of more than 1,400 US cancer patients
Novocure, an oncology company, disclosed a cybersecurity incident that exposed internal records of over 1,400 US cancer patients, primarily patient ID numbers. A smaller group of fewer than 50 patients had more identifying information accessed, along with contact details of an undisclosed number of employees. The company stated that its medical treatment devices and operations were unaffected, and it is reviewing notification obligations.
Oncology firm Novocure says cyberattack exposed US patient records
Oncology company Novocure disclosed a cybersecurity incident in mid-August that resulted in unauthorized access to its systems, exposing internal records of over 1,400 U.S. patients. The exposed data includes patient IDs, contact information for healthcare providers and Novocure employees, and additional identifying information for fewer than 50 patients. The company stated that access to its medical devices was not compromised and expects no material financial impact from the breach.
Oncology firm Novocure says cyberattack exposed US patient records
Oncology company Novocure reported a cyberattack in mid-August that exposed internal records of over 1,400 U.S. patients, including company patient IDs and contact information for healthcare providers and employees. While access to medical treatment devices was not gained and all systems are functional, the incident adds to a growing number of cyberattacks in the healthcare sector. Novocure anticipates no material financial impact from the breach.
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
NovoCure (NVCR) has seen an 18.1% gain over the past four weeks, with Wall Street analysts projecting a potential 50.9% upside based on a mean price target of $27.14. Despite a high standard deviation in individual targets, analyst optimism about the company's earnings prospects, supported by upward EPS estimate revisions and a Zacks Rank #2 (Buy), suggests a legitimate reason for potential stock upside. However, the article cautions against solely relying on price targets due to their inherent biases and historical unreliability.
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors?
NovoCure (NVCR) has received an upgraded Momentum Style Score of B and a Zacks Rank of #2 (Buy) due to recent upward earnings estimate revisions. While this indicates growing confidence in its near-term earnings and tumor treating fields platform, the core investment narrative, execution in new indications, and physician adoption remain key factors. The company recently raised its full-year net revenue guidance and narrowed losses, but investors should still consider the risks associated with reliance on a single technology.
Novocure | 8-K: Current report
This article is a current report (8-K) filed by Novocure. The content is simply "Document", indicating that the full details of the 8-K filing would be contained within an attached document, which is not provided here.
What’s Behind NovoCure (NVCR) Shares Climbing Today?
NovoCure (NVCR) shares have seen recent positive momentum, with a 10.11% gain over the past month and 33.61% year-to-date, despite an 87.03% decline over five years. The company is considered 32.8% undervalued with a fair value of $26.07, driven by potential regulatory approvals for its TTFields therapy and expected market expansion in oncology. However, risks like slower adoption and reimbursement uncertainty could challenge this valuation.
What’s Behind NovoCure (NVCR) Shares Climbing Today?
NovoCure (NVCR) shares have seen recent positive momentum, with a 10.11% gain over the last month, despite an 87.03% decline in total shareholder return over five years. The company is currently considered 32.8% undervalued, with a fair value of $26.07 compared to its recent close of $17.53, driven by potential regulatory approvals and market expansion for its TTFields therapy. However, risks like slower adoption and reimbursement uncertainty could challenge this valuation.
NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials Progress - Has The Bull Case Changed?
NovoCure (NVCR) shares rose 8.5% following updates on its tumor treating fields (TTFields) pipeline, including devices like Optune Gio and Optune Lua, and progress in clinical trials for solid tumor cancers. While these advancements reinforce the long-term investment thesis for TTFields, the recent TRIDENT Phase 3 trial for glioblastoma did not meet its primary survival endpoint, tempering near-term expectations for broader adoption. Investors are encouraged to weigh the potential for scaling revenues against ongoing losses and uneven clinical outcomes.
NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials Progress - Has The Bull Case Changed?
NovoCure (NVCR) recently reported progress in its tumor treating fields pipeline, including Optune Gio and Optune Lua, and ongoing clinical trials for solid tumor cancers. While the TRIDENT Phase 3 trial for glioblastoma did not meet its primary survival endpoint, the company's long-term investment narrative still hinges on the broad adoption of its non-invasive cancer therapies. Investors are encouraged to assess the bullish revenue and earnings projections against the risks of clinical trial outcomes and reimbursement challenges.
NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials Progress - Has The Bull Case Changed?
NovoCure (NVCR) saw an 8.5% stock increase following advancements in its tumor treating fields pipeline, including devices like Optune Gio and Optune Lua, and progress in clinical trials for solid tumor cancers. While these developments reinforce the core thesis around TTFields technology, the investment narrative is nuanced by the recent Phase 3 TRIDENT trial in glioblastoma missing its primary survival endpoint. Investors are encouraged to weigh these ongoing developments and persistent losses against the potential long-term role of non-invasive cancer therapies.
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued
NovoCure (NVCR) stock has seen recent optimism due to its tumor treating fields devices and potential FDA approval, leading to a strong short-term share price increase. Despite positive short-term performance, its long-term returns are negative, yet its fair value is estimated to be significantly higher than its current trading price. The company's future relies heavily on the adoption and reimbursement of its TTFields technology and potential expansion into new indications.
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued
NovoCure (NVCR) is experiencing renewed investor optimism due to its tumor treating fields (TTFields) devices and potential FDA approval, leading to a recent stock price surge despite long-term declines. The company is currently considered 33.6% undervalued with a fair value pegged at $26.07, driven by expectations of market expansion and revenue growth from new indications. However, risks remain if TTFields adoption or reimbursement progress stalls, as the business relies heavily on this single core technology.
First Trust Advisors LP Invests $1.03 Million in NovoCure Limited $NVCR
First Trust Advisors LP has invested $1.03 million in NovoCure Limited by acquiring 94,293 shares. Institutional investors collectively own 84.61% of the company, and NovoCure recently reported strong quarterly revenue and a better-than-expected adjusted loss. Analysts currently maintain a "Hold" rating for the stock with an average price target of $21.20.
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued
NovoCure (NVCR) is experiencing renewed optimism due to its tumor treating fields devices and hopes for upcoming FDA approval, leading to a recent surge in its stock price. Despite significant short-term gains, the stock has seen declines over three and five years. Analysts consider NovoCure undervalued, with a fair value estimate of $26.07 against its current price of $17.31, driven by potential market expansion and regulatory approvals for new indications of its TTFields therapy.
NovoCure (NASDAQ:NVCR) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded NovoCure (NASDAQ:NVCR) to a "Buy" rating, despite a broader analyst consensus of "Hold" with an average price target of $21.20. The upgrade follows NovoCure's strong quarterly results, where adjusted EPS loss of $0.13 significantly beat the anticipated $0.33 loss, and revenue increased by 15.6% year-over-year to $183.58 million. The stock saw a 4.5% rise, opening at $16.39, with institutional investors holding 84.61% of shares, while insiders have sold a minor amount to cover tax obligations.
Novocure Ltd (NVCR) Stock Analysis & Forecast
Novocure Ltd (NVCR) saw its stock surge to $19.91 following stronger-than-expected Q2 2026 earnings. The company reported revenue that exceeded consensus estimates, growing 8.6% year-over-year. This recovery is primarily attributed to the FDA approval and multi-indication expansion of its Optune Pax treatment, especially after the prior TRIDENT trial disappointment.
NovoCure Number of Employees 2026 | Employee Count & Headcount Data
NovoCure Ltd. (NVCR) has approximately 1,630 employees worldwide as of March 2026, representing a 10.4% growth from 2023. The company is actively hiring, with 151 job postings in 2026. The workforce is concentrated in North America, Western Europe, and Central and Western Asia, with an average salary of $105,002 globally.
NovoCure (NVCR) Stock Looks Undervalued With Shares Down 90% Over Five Years
NovoCure (NVCR) shares have dropped significantly by 90% over the last five years, yet the stock appears undervalued based on several metrics, including a high value score from Simply Wall St. Despite recent commercial progress with its Tumor Treating Fields therapies and a higher revenue outlook, the company's valuation remains discounted compared to its fair P/S ratio and industry peers. The core debate for investors revolves around whether the current price sufficiently accounts for past performance and ongoing risks, or if recent improvements signal potential for future upside.
NovoCure (NVCR) Stock Looks Undervalued With Shares Down 90% Over Five Years
NovoCure (NVCR) stock has seen a 90% decline over the past five years, yet recent valuations suggest it may be undervalued, particularly on a price-to-sales basis. The company's progress in Tumor Treating Fields therapies and record quarterly sales point to potential upside, though legal investigations and a history of losses present ongoing risks. Investors are currently weighing whether the current share price adequately reflects these risks and the potential for future profitability.
NVCR|Novocure Ltd|Price:15.180|Chg%:-0.020
This article provides a comprehensive stock analysis of Novocure Ltd (NVCR), highlighting its relatively healthy fundamentals, high growth potential with 28.67% average revenue growth over three years, and fair valuation. Despite a recent weak stock market performance, the company shows strong fundamentals and has a high institutional ownership of 99.30M shares. Analysts currently rate NVCR as a "Buy" with a target price of 28.833, suggesting a 69.31% upside.
NovoCure Ltd. Revenue Breakdown – DUS:038
This article provides a revenue breakdown for NovoCure Ltd. (DUS:038), showing that the company generated EUR 557.98 million last year, primarily from its Tumor Treating Fields segment. The United States was the largest contributor to revenue, accounting for EUR 328.33 million. The previous year's total revenue was EUR 584.63 million.
Novocure Ltd (NVCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Novocure Ltd (NVCR), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. According to the analysis, NVCR is suitable for range-bound swing trading, with its price momentum ranking 50 out of 199 in its industry. The technical indicators show mixed signals, recommending a "Neutral" stance, while moving averages suggest a mix of buy and sell signals.
Novocure Hits Record Revenue & Raises 2026 Outlook
Novocure (NVCR) reported record quarterly revenue of US$183.6 million in Q2 2026 and raised its full-year 2026 guidance to US$710-725 million. The company's Optune Pax therapy received CE Mark approval for pancreatic cancer, facilitating its first European launch in Germany, and active patient numbers grew across all marketed therapies. A major catalyst could be the upcoming FDA decision on brain metastases treatment in Q4 2026, which analysts are closely watching.
NovoCure Market Sentiment
This article analyzes the market sentiment for NovoCure (NVCR) based on key indicators including analyst consensus, short interest, options flow, and insider activity. It highlights that while analysts largely recommend a "Buy," the options flow suggests a bearish sentiment, and the short interest is rising. The article also provides a detailed list of recent analyst actions, price targets, and ratings for NovoCure.
Novocure Ltd (NVCR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Novocure Ltd (NVCR)'s dividend and stock split history, indicating that no dividends have been distributed in the past five years. It also includes current stock performance data and company information. The page states that investment products carry significant risks and advises that past performance isn't indicative of future results.
Novocure Posts Record Q2 Revenue of US$183.6M
Novocure (NVCR:NASDAQ) reported record Q2 2026 revenue of US$183.6 million, a 16% increase year-over-year, leading the company to raise its full-year guidance to US$710-US$725 million. The oncology company also announced the CE Mark approval for Optune Pax for pancreatic cancer and saw its net loss narrow and adjusted EBITDA turn positive. Analysts have mixed views, with some reiterating "Neutral" ratings while others maintain "Buy" ratings and higher price targets based on the company's sustained growth and expanding therapy portfolio.
Transcript: NovoCure Q2 2026 Earnings Conference Call
NovoCure reported record net revenues of $184 million in Q2 2026, a 16% year-over-year increase, driven by growth in Optune Gio, Lua, and Pax, with an 11% rise in active Optune Gio patients. The company updated its full-year revenue guidance to $710-$725 million and aims for profitability by the end of 2026 through revenue growth and cost management, including a redesigned LUNAR-2 trial to save $90 million. NovoCure is strategically expanding Tumor Treating Fields (TTFields) in new cancer indications like pancreatic cancer, planning additional trials, and IDE studies for combining TTFields with RAS inhibitors.
NovoCure (NVCR) Is Up 10.9% After Raising 2026 Revenue Outlook and Securing New CE Mark Approval – Has The Bull Case Changed?
NovoCure (NVCR) saw its stock rise 10.9% after reporting its strongest Q2 ever, with a revenue increase to US$183.58 million, a reduced net loss, and an upgraded 2026 revenue outlook of US$710-US$725 million. The company also secured a CE Mark for its Optune Pax device for pancreatic cancer and anticipates FDA approval for brain metastases from NSCLC, strengthening its indication expansion strategy. While this improves the near-term outlook for achieving positive adjusted EBITDA, investors should remain aware of potential reimbursement challenges.
NovoCure Ltd. Revenue Breakdown – LSX:A140ML
NovoCure Ltd. generated €557.98 million in revenue last year, primarily from its Tumor Treating Fields segment. This represents a slight decrease from the previous year's €584.63 million. The United States was the largest contributor to revenue, accounting for €328.33 million.
